Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level.

Area of Science:

• Biotechnology
• Nanomedicine
• Drug Delivery

Background:

• Lipid nanoparticles (LNPs) are a promising drug delivery platform with broad experimental, diagnostic, and therapeutic potential.
• Current limitations include preferential accumulation in hepatocytes and antigen-presenting cells, restricting clinical use mainly to vaccines and liver disease treatments.
• Overcoming these targeting issues is crucial for unlocking the full therapeutic capacity of LNP technology.

Purpose of the Study:

• To review established and emerging techniques for monitoring the in vivo behavior of RNA-loaded LNPs (RNA-LNPs).
• To explore strategies for enhanced tissue and cell targeting to broaden LNP applications.
• To discuss advancements that accelerate the clinical translation of RNA-LNP therapeutics.

Main Methods:

• Review of current literature on LNP monitoring techniques.
• Analysis of bioengineering and LNP chemistry innovations for improved targeting.
• Exploration of synthetic biology approaches, including microRNA target sites and protein modification, to control mRNA cargo expression, stability, and localization.

Main Results:

• Established and novel methods for tracking RNA-LNPs in vivo are presented.
• Strategies involving LNP chemistry, bioengineering, and synthetic biology offer improved tissue and cell specificity.
• Modifications to mRNA cargo and encoded proteins can enhance payload stability and subcellular targeting.

Conclusions:

• Advanced monitoring and targeting strategies are expanding the clinical utility of RNA-LNPs beyond current limitations.
• Innovations in LNP design and cargo engineering are key to improving therapeutic outcomes.
• These advancements facilitate the broader clinical translation of RNA-LNP-based therapies.